AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14560062 — intervention group
Group type: COMPARATOR
Intervention: Placebo to Galantamine (open-label phase)
Number of subjects: 285
Study 14560062 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (continuous treatment)
Number of subjects: 285
Study 11708713 — intervention group
Group type: EXPERIMENTAL
Intervention: Small Increment (SI) progressive resistance exercise
Number of subjects: 19
Study 11708713 — intervention group
Group type: COMPARATOR
Intervention: Traditional (TRAD) progressive resistance exercise
Number of subjects: 19
Study 8702377 — intervention group
Group type: EXPERIMENTAL
Intervention: Random practice
Number of subjects: 24
Study 8702377 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked practice
Number of subjects: 24
Study 8702377 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 2008110 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose allopurinol (total dose 1200 mg)
Number of subjects: 90
Study 2008110 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose allopurinol (total dose 2400 mg)
Number of subjects: 90
Study 2008110 — intervention group
Group type: COMPARATOR
Intervention: No allopurinol
Number of subjects: 90
Study 7123294 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine mixed with contrast medium
Number of subjects: 34
Study 31846898 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication of the diagnosis of PNES
Number of subjects: 54
Study 31846898 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 54
Study 30362173 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg
Number of subjects: 909
Study 28934640 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF-1/rhIGFBP-3
Number of subjects: 19
Study 28934640 — intervention group
Group type: COMPARATOR
Intervention: Standard neonatal care
Number of subjects: 19
Study 25294666 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength RT with 60‐s rest intervals (SS)
Number of subjects: 22
Study 25294666 — intervention group
Group type: COMPARATOR
Intervention: Strength RT with 4‐min rest intervals (SL)
Number of subjects: 22
Study 23416318 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) on the dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 0
Study 23416318 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 22428485 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 microg/kg bolus followed by 0.4 microg/kg/hr infusion)
Number of subjects: 40
Study 22428485 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 40
Study 19398283 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (20mg q.i.d. titrated upwards over twelve days)
Number of subjects: 30
Study 19398283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 17312229 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 1 mg
Number of subjects: 176
Study 17312229 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 176
Study 15193851 — intervention group
Group type: EXPERIMENTAL
Intervention: Hawaii Healthy Start Program (HSP)
Number of subjects: 643
Study 15193851 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 643
Study 11641075 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrarectal quinine (QIR) 20 mg/kg in solution with 2 ml of water, followed by 15 mg/kg/8 h for cerebral malaria; 30 mg/kg followed by 20 mg/kg/12 h for severe malaria.
Number of subjects: 133
Study 11641075 — intervention group
Group type: COMPARATOR
Intervention: Intrarectal quinine (QIR)
Number of subjects: 133
Study 9613298 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (0.3, 0.6, 0.9, 1.2 vol.%)
Number of subjects: 36
Study 9613298 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (1.5, 3.0, 4.5, 6.0 vol.%)
Number of subjects: 36
Study 9613298 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (0.5, 1.0, 1.5, 2.0 vol.%)
Number of subjects: 36
Study 7906384 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine (500 mg per day)
Number of subjects: 467
Study 7906384 — intervention group
Group type: COMPARATOR
Intervention: Zalcitabine (2.25 mg per day)
Number of subjects: 467
Study 7906384 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 467
Study 1982648 — intervention group
Group type: EXPERIMENTAL
Intervention: Potenlini treatment (daily intravenous drip of 60‐100 ml for 3 days)
Number of subjects: 439
Study 1982648 — intervention group
Group type: COMPARATOR
Intervention: Control group (other measures of treatment same as therapeutic group)
Number of subjects: 439
Study 230693 — intervention group
Group type: EXPERIMENTAL
Intervention: ethinyl estradiol 50 micrograms + levonorgestrel 125 micrograms (50/125)
Number of subjects: 75
Study 230693 — intervention group
Group type: EXPERIMENTAL
Intervention: ethinyl estradiol 50 micrograms + levonorgestrel 250 micrograms (50/250)
Number of subjects: 75
Study 230693 — intervention group
Group type: EXPERIMENTAL
Intervention: ethinyl estradiol 30 micrograms + levonorgestrel 150 micrograms (30/150)
Number of subjects: 75
Study 30868787 — intervention group
Group type: EXPERIMENTAL
Intervention: Open treatment
Number of subjects: 0
Study 30868787 — intervention group
Group type: COMPARATOR
Intervention: Closed treatment
Number of subjects: 0
Study 27773578 — intervention group
Group type: EXPERIMENTAL
Intervention: PMA + RA (n = 48)
Number of subjects: 96
Study 27773578 — intervention group
Group type: COMPARATOR
Intervention: RA alone (n = 48)
Number of subjects: 96
Study 23096064 — intervention group
Group type: EXPERIMENTAL
Intervention: Low amplitude group (GL)
Number of subjects: 38
Study 23096064 — intervention group
Group type: EXPERIMENTAL
Intervention: High amplitude group (GH)
Number of subjects: 38
Study 23096064 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study 21663459 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide
Number of subjects: 0
Study 19846008 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-stretch group (pressure assist control mode with peak pressure not higher than 35 cm H(2)O or pressure support mode with Pplateau not higher than 30 cm H(2)O)
Number of subjects: 85
Study 19846008 — intervention group
Group type: COMPARATOR
Intervention: Low-tidal-volume group (tidal volume no more than 6 ml/kg of predicted body weight)
Number of subjects: 85
Study 19846008 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-stretch group
Number of subjects: 85
Study 19846008 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-stretch subgroup (V(T)e ≤6 ml/kg)
Number of subjects: 85
Study 19846008 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-low-tidal-volume subgroup (V(T)e >6 ml/kg)
Number of subjects: 85
Study 19846008 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-tidal-volume subgroup (V(T)e ≤6 ml/kg)
Number of subjects: 85
Study 17241418 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical botulinum toxin type A (BTX‐A) 200 U applied to one axilla
Number of subjects: 12
Study 17241418 — intervention group
Group type: COMPARATOR
Intervention: Vehicle without BTX‐A applied to the other axilla
Number of subjects: 12
Study 15027057 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysport
Number of subjects: 164
Study 15027057 — intervention group
Group type: COMPARATOR
Intervention: BOTOX
Number of subjects: 164
Study 11686231 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradication of H. pylori with lansoprazole and antibiotics
Number of subjects: 0
Study 11686231 — intervention group
Group type: COMPARATOR
Intervention: Acid-suppressant treatment alone (lansoprazole)
Number of subjects: 0
Study 11686231 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradication of H. pylori
Number of subjects: 0
Study 9231834 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (10, 20, or 40 mg)
Number of subjects: 232
Study 9231834 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (12.5, 25, or 50 mg)
Number of subjects: 232
Study 9231834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study 8136647 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixt. 716 treatment group
Number of subjects: 150
Study 8136647 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study 8136647 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixt. 716
Number of subjects: 150
Study 3524840 — intervention group
Group type: EXPERIMENTAL
Intervention: Etretinate therapy (4 months)
Number of subjects: 15
Study 3524840 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 months)
Number of subjects: 15
Study 3524840 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after etretinate therapy)
Number of subjects: 15
Study 29504793 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive-behavioral treatment (ICBT) with systematic exposure
Number of subjects: 309
Study 29504793 — intervention group
Group type: COMPARATOR
Intervention: Internet-delivered cognitive-behavioral treatment (ICBT) without exposure (ICBT-WE)
Number of subjects: 309
Study 27664129 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish
Number of subjects: 78
Study 27664129 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 78
Study 23711620 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration training (squat positioned on a vibration platform, 3 times per week for 11 weeks)
Number of subjects: 49
Study 23711620 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 49
Study 22052452 — intervention group
Group type: EXPERIMENTAL
Intervention: ronacaleret 100 mg once daily
Number of subjects: 569
Study 22052452 — intervention group
Group type: COMPARATOR
Intervention: teriparatide 20 µg subcutaneously once daily
Number of subjects: 569
Study 22052452 — intervention group
Group type: COMPARATOR
Intervention: alendronate 70 mg once weekly
Number of subjects: 569
Study 22052452 — intervention group
Group type: EXPERIMENTAL
Intervention: ronacaleret
Number of subjects: 569
Study 22052452 — intervention group
Group type: COMPARATOR
Intervention: teriparatide
Number of subjects: 569
Study 22052452 — intervention group
Group type: COMPARATOR
Intervention: alendronate
Number of subjects: 569
Study 19462823 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 0
Study 19462823 — intervention group
Group type: COMPARATOR
Intervention: Eviprostat
Number of subjects: 0
Study 17452893 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) with corticosteroids
Number of subjects: 44
Study 17452893 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CsA) with corticosteroids
Number of subjects: 44
Study 15103688 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular vaccine for children >4 years of age, adolescents, and adults
Number of subjects: 100
Study 11669028 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (ABZ) 400 mg suspension every six months plus Vitamin A 2 ml (1 ml for infants)
Number of subjects: 2010
Study 11669028 — intervention group
Group type: COMPARATOR
Intervention: Control group received Vitamin A 2 ml (1 ml for infants) every six months
Number of subjects: 2010
Study 11669028 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (ABZ) plus Vitamin A
Number of subjects: 2010
Study 9850906 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutureless closure
Number of subjects: 75
Study 9850906 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperatively adjusted cross suture
Number of subjects: 75
Study 9850906 — intervention group
Group type: EXPERIMENTAL
Intervention: Unadjusted cross suture
Number of subjects: 75
Study 9850906 — intervention group
Group type: COMPARATOR
Intervention: Sutured cases
Number of subjects: 75
Study 7991321 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-retest reliability
Number of subjects: 66
Study 7991321 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-teacher agreement
Number of subjects: 66
Study 2733949 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate oxytocin induction (86 women)
Number of subjects: 182
Study 2733949 — intervention group
Group type: COMPARATOR
Intervention: Expectant management with oxytocin induction at 24 hours if labor had not occurred spontaneously (96 women)
Number of subjects: 182
Study 6340081 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin
Number of subjects: 147
Study 30295729 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Mood and Active Life (PMAL) program
Number of subjects: 68
Study 30295729 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 68
Study 31271338 — intervention group
Group type: EXPERIMENTAL
Intervention: Previously medicated patients
Number of subjects: 226
Study 31271338 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic-naïve patients
Number of subjects: 226
Study 27660922 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy (twice a day for 5 days)
Number of subjects: 140
Study 27059671 — intervention group
Group type: EXPERIMENTAL
Intervention: HydE (9 g daily for 6 months)
Number of subjects: 29
Study 27059671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 27059671 — intervention group
Group type: EXPERIMENTAL
Intervention: HydE
Number of subjects: 29
Study 24311763 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg daily for 3 months followed by 200 mg daily for 21 months
Number of subjects: 23
Study 24311763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 24311763 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 23
Study 22912452 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicarbazin (NCZ) at 125 mg/kg
Number of subjects: 12
Study 22912452 — intervention group
Group type: COMPARATOR
Intervention: Salinomycin at 66 mg/kg
Number of subjects: 12
Study 20706922 — intervention group
Group type: EXPERIMENTAL
Intervention: Paid group intervention
Number of subjects: 197
Study 20706922 — intervention group
Group type: EXPERIMENTAL
Intervention: Paid individual intervention
Number of subjects: 197
Study 20706922 — intervention group
Group type: COMPARATOR
Intervention: Unpaid group intervention
Number of subjects: 197
Study 17548672 — intervention group
Group type: EXPERIMENTAL
Intervention: CAT TT genotype among men diagnosed before age 65
Number of subjects: 724
Study 17548672 — intervention group
Group type: COMPARATOR
Intervention: Carriage of five or more risk alleles of MnSOD, CAT, and GPX1
Number of subjects: 724
Study 15823830 — intervention group
Group type: EXPERIMENTAL
Intervention: Relcovaptan (400 mg)
Number of subjects: 18
Study 15823830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 12240516 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized care plan
Number of subjects: 20
Study 12240516 — intervention group
Group type: COMPARATOR
Intervention: Paper care plan
Number of subjects: 20
Study 12240516 — intervention group
Group type: EXPERIMENTAL
Intervention: Both care plans
Number of subjects: 20
Study 9578817 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioiodine treatment (RAI) with a median dose of 555 MBq
Number of subjects: 28
Study 9578817 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 28
Study 8124790 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 244
Study 8124790 — intervention group
Group type: EXPERIMENTAL
Intervention: Alinidine
Number of subjects: 244
Study 8124790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study 8124790 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic treatment
Number of subjects: 244
Study 2518859 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg famotidine nightly
Number of subjects: 208
Study 2518859 — intervention group
Group type: COMPARATOR
Intervention: 150 mg ranitidine b.d.
Number of subjects: 208
Study 193359 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH 4-10
Number of subjects: 0
Study 193359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30959747 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component intervention promoting physical activity (PA) through group meetings, photo-sharing, and action plans
Number of subjects: 204
Study 30959747 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component intervention promoting physical activity (PA)
Number of subjects: 204
Study 30959747 — intervention group
Group type: COMPARATOR
Intervention: Waitlisted control group (CG)
Number of subjects: 204
Study 28286933 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrostomy tract infiltration of 20 mL saline solution containing 1.5 mg/kg ketamine
Number of subjects: 66
Study 28286933 — intervention group
Group type: COMPARATOR
Intervention: Control group with 20 mL saline solution infiltrated into the nephrostomy tract
Number of subjects: 66
Study 28286933 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 66
Study 25217311 — intervention group
Group type: COMPARATOR
Intervention: Conventional instruments (CON)
Number of subjects: 81
Study 25217311 — intervention group
Group type: COMPARATOR
Intervention: Patient-specific instruments (PSI)
Number of subjects: 81
Study 25217311 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer navigation (NAV)
Number of subjects: 81
Study 25217311 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (CON, NAV, PSI)
Number of subjects: 81
Study 23850859 — intervention group
Group type: EXPERIMENTAL
Intervention: Service brokerage intervention (personalised booklet and weekly telephone contact for 4 weeks post-release)
Number of subjects: 1325
Study 23850859 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1325
Study 21510365 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved anatomic-functional model for estimating injury severity and prognosticating traumatic disease course
Number of subjects: 0
Study 19365397 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic heparin (study group)
Number of subjects: 297
Study 19365397 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (control group)
Number of subjects: 297
Study 18091183 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy with mitomycin C (T+MMC)
Number of subjects: 30
Study 18091183 — intervention group
Group type: COMPARATOR
Intervention: Ahmed glaucoma implant with mitomycin C (AGI+MMC)
Number of subjects: 30
Study 15072248 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte-depletion group (n = 13)
Number of subjects: 26
Study 15072248 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 13)
Number of subjects: 26
Study 11642577 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant dosage intranasal immunotherapy
Number of subjects: 43
Study 11642577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 20673423 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradiscal oxygen-ozone injection
Number of subjects: 93
Study 8044941 — intervention group
Group type: EXPERIMENTAL
Intervention: ranolazine 30 mg tid
Number of subjects: 318
Study 8044941 — intervention group
Group type: EXPERIMENTAL
Intervention: ranolazine 60 mg tid
Number of subjects: 318
Study 8044941 — intervention group
Group type: EXPERIMENTAL
Intervention: ranolazine 120 mg tid
Number of subjects: 318
Study 8044941 — intervention group
Group type: COMPARATOR
Intervention: placebo tid
Number of subjects: 318
Study 3378659 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin administered intravenously or intramuscularly every 12 h at a dosage of 2.0-4.4 mg/kg (mean 3.5 mg/kg) for 5-15 days (mean 11 days)
Number of subjects: 34
Study 3378659 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin administered intravenously or intramuscularly
Number of subjects: 34
Study 3378659 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin therapy
Number of subjects: 34
Study 31233629 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% fluorocalcium phosphosilicate toothpaste (Group A)
Number of subjects: 75
Study 31233629 — intervention group
Group type: COMPARATOR
Intervention: 8% arginine and calcium carbonate toothpaste (Group B)
Number of subjects: 75
Study 31233629 — intervention group
Group type: COMPARATOR
Intervention: Placebo toothpaste (Group C)
Number of subjects: 75
Study 28377394 — intervention group
Group type: EXPERIMENTAL
Intervention: Suanzaoren decoction (SZRD) granule plus zolpidem tartrate (ZT) placebo
Number of subjects: 150
Study 28377394 — intervention group
Group type: COMPARATOR
Intervention: Zolpidem tartrate (ZT) tablet plus SZRD granule placebo
Number of subjects: 150
Study 28377394 — intervention group
Group type: COMPARATOR
Intervention: Zolpidem tartrate (ZT) placebo and SZRD granule placebo
Number of subjects: 150
Study 26129925 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin analogues
Number of subjects: 96
Study 26129925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 23831492 — intervention group
Group type: EXPERIMENTAL
Intervention: LHE-delivered 12-session translation of the Diabetes Prevention Program (DPP)
Number of subjects: 116
Study 21569471 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist Medical and Mental Health Unit
Number of subjects: 300
Study 21569471 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 300
Study 19298568 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroanatomically guided ablation (Carto)
Number of subjects: 210
Study 19298568 — intervention group
Group type: COMPARATOR
Intervention: Conventional ablation
Number of subjects: 210
Study 16821349 — intervention group
Group type: EXPERIMENTAL
Intervention: SpeediCath Set
Number of subjects: 29
Study 16821349 — intervention group
Group type: COMPARATOR
Intervention: Actreen Set
Number of subjects: 29
Study 15266206 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE disclosure in a risk assessment protocol
Number of subjects: 0
Study 15266206 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE odds ratios
Number of subjects: 0
Study 10667721 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyflux membrane
Number of subjects: 0
Study 10667721 — intervention group
Group type: COMPARATOR
Intervention: Fresenius Polysulfone membrane
Number of subjects: 0